Your browser doesn't support javascript.
loading
Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?
Gómez-Aparicio, María Antonia; López-Campos, Fernando; Buchser, David; Lazo, Antonio; Willisch, Patricia; Ocanto, Abrahams; Sargos, Paul; Shelan, Mohamed; Couñago, Felipe.
Afiliación
  • Gómez-Aparicio MA; Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain.
  • López-Campos F; Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
  • Buchser D; Department of Radiation Oncology, Hospital Universitario San Francisco de Asis and Hospital Vithas La Milagrosa, GenesisCare, 28002 Madrid, Spain.
  • Lazo A; Department of Radiation Oncology, Hospital Universitario Cruces, 48903 Barakaldo, Spain.
  • Willisch P; Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain.
  • Ocanto A; Department of Radiation Oncology, Hospital Meixoeiro, 36214 Vigo, Spain.
  • Sargos P; Department of Radiation Oncology, Hospital Universitario San Francisco de Asis and Hospital Vithas La Milagrosa, GenesisCare, 28002 Madrid, Spain.
  • Shelan M; Department of Radiation Oncology, Institut Bergonié, 33000 Bordeaux, France.
  • Couñago F; Department of Radiation Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
Cancers (Basel) ; 16(13)2024 Jun 26.
Article en En | MEDLINE | ID: mdl-39001393
ABSTRACT
The treatment landscape for metastatic hormone-sensitive prostate cancer continues to evolve, with systemic treatment being the mainstay of current treatment. Prognostic and predictive factors such as tumour volume and disease presentation have been studied to assess responses to different treatments. Intensification and de-escalation strategies arouse great interest, so several trials are being developed to further personalize the therapy in these populations. Is there an optimal sequence and a possible option to de-intensify treatment in selected patients with a favourable profile? This and other goals will be the subject of this review.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza